1cP-LSD

Discovery

1cP-LSD first appeared on the online research chemical market in approximately July 2019.^[3] Unlike earlier lysergamides such as ALD-52, which emerged from academic ergoline research in the 1950s, 1cP-LSD has no published synthesis precedent and appears to have been designed specifically for commercial distribution. Brandt et al. provided the first scientific characterization in 2020, confirming its conversion to LSD in human serum and documenting behavioral activity in mice at approximately 32% of LSD potency.^[3]

The lysergamide series

1cP-LSD was the sixth compound documented in Brandt et al.'s "Return of the Lysergamides" publication series, which tracked N1-acylated LSD derivatives as they appeared on the market.^[3] The series spans 1P-LSD (2016),^[11] LSM-775 (Part IV),^[12] 1B-LSD (2019),^[13] 1V-LSD (2022),^[14] and 1F-LSD (2025).^[15] Each publication confirmed the same class principle: N1-acylation weakens direct receptor activity, but the body's hydrolysis rapidly restores LSD-level potency.

Regulatory succession

The sequential emergence of these derivatives reflects a regulatory arms race between research chemical producers and scheduling authorities.^[4] 1cP-LSD became the dominant legal lysergamide in Germany after 1P-LSD was captured by the NpSG; when 1cP-LSD itself was banned in July 2021,^[16] 1V-LSD was marketed as its replacement. Tanaka et al. confirmed international distribution by late 2019 through forensic detection in Japanese blotter products.^[17]

Structural class

1cP-LSD belongs to the lysergamide class — ergoline alkaloids sharing the tetracyclic indole-fused ring system of d-lysergic acid. The defining modification is a cyclopropanecarbonyl group attached at the N1 (indole nitrogen) position, placing it in the N1-acylated LSD derivative series alongside 1P-LSD (propanoyl), 1B-LSD (butanoyl), and 1V-LSD (valeroyl).^[3]

This N1-acyl modification reduces direct binding at serotonin receptors but permits the body to cleave the acyl group, regenerating LSD — functionally converting these derivatives into prodrugs.^[15][14] The cyclopropane ring in 1cP-LSD's acyl group introduces distinct steric properties compared with the straight-chain substituents of related derivatives, though the pharmacological consequences of this specific difference have not been isolated.^[18]

Molecular properties

The molecular formula reflects the addition of a cyclopropanecarbonyl group (C₄H₅O) to the LSD scaffold (C₂₀H₂₅N₃O, 323.4 g/mol), yielding a 68.1 g/mol mass increase. The compound is distributed on blotter paper and in pellet form.^[3]

Stereochemistry

1cP-LSD retains the (6aR,9R) absolute configuration of d-lysergic acid diethylamide — the pharmacologically active stereoisomer. No characterization of the inactive epimer has been published.

Analytical considerations

Tusiewicz et al. demonstrated that methanol causes breakdown of N1-acyl LSD derivatives — including 1cP-LSD — producing LSD as an analytical artifact.^[19] This has implications for both forensic identification and harm reduction testing: methanol-based preparations may incorrectly indicate LSD rather than its prodrug. Stable analysis requires non-protic solvents such as diethyl ether or dichloromethane.^[19]

Mechanism of action

1cP-LSD is a prodrug of LSD. The intact compound has weak or no activity at serotonin receptors — the cyclopropanecarbonyl group at the indole nitrogen blocks receptor binding. In the body, this group is cleaved by serum enzymes, releasing active LSD. Brandt et al. confirmed this conversion by incubating 1cP-LSD with human serum at body temperature and observing time-dependent LSD formation.^[3]

This prodrug mechanism is shared across the entire N1-acylated series. It was definitively demonstrated in human subjects for 1P-LSD, where oral administration produced detectable serum LSD with no detectable parent compound.^[20] The same principle has been confirmed for 1V-LSD^[14] and 1F-LSD.^[15]

In the mouse head-twitch response assay — the standard behavioral proxy for psychedelic activity — 1cP-LSD showed approximately 32% of LSD's potency.^[3] This reduced potency reflects partial hydrolysis under acute experimental conditions rather than inherently weaker activity of the released LSD.

Once hydrolyzed, the pharmacological profile is identical to LSD at all characterized receptor targets, with 5-HT₂A activation as the primary driver of psychedelic effects.^[1][2]

Pharmacokinetics

No human pharmacokinetic data have been published for 1cP-LSD. All parameters are inferred from the confirmed prodrug structural analog 1P-LSD and from LSD reference studies.

For 1P-LSD, Grumann et al. demonstrated in two human volunteers that oral administration of 100 µg yielded only LSD in blood and urine, with an LSD half-life of approximately 5.7 hours and estimated bioavailability approaching 100%.^[20] By structural analogy, oral 1cP-LSD undergoes rapid conversion to LSD, and the experience reflects LSD pharmacokinetics thereafter.

The onset delay of 20–60 minutes reported by users is consistent with the time required for hydrolysis before active LSD reaches circulation.^[21] LSD itself reaches peak plasma concentrations in 1.5–2 hours, with subjective effects lasting 6.7–11 hours dose-dependently.^[5] Oral bioavailability of LSD is approximately 80%,^[22] with a plasma half-life of 2.6–3.6 hours.^[23]

Individual variation in experience intensity correlates with CYP2D6 enzyme function, which governs LSD metabolism in the liver.^[6] Whether the additional hydrolysis step introduces a further source of variability is unknown. The cyclopropanoic acid released during hydrolysis has not been studied for biological activity or toxicity.^[3]

Where it acts

As a prodrug of LSD, 1cP-LSD engages the same neural systems documented in LSD neuroimaging research. LSD acts primarily on 5-HT₂A receptors on pyramidal neurons in the prefrontal cortex, disrupting the default mode network — the brain's resting-state system for self-referential thought and narrative identity. This disruption underlies the experience of ego dissolution and boundary loss.^[9]

Simultaneously, LSD disrupts the thalamus's normal filtering of sensory input, allowing increased sensory throughput and cross-modal processing. This gating failure contributes to perceptual intensification, synesthesia, and geometric visual phenomena.^[9] At the whole-brain level, LSD increases global connectivity and neural entropy — a shift from modular, constrained processing toward a more interconnected state that correlates dose-dependently with subjective intensity.^[5]

Why it matters

The REBUS (Relaxed Beliefs Under Psychedelics) model offers the most integrative framework: psychedelics relax the brain's confidence in its existing beliefs and expectations, allowing raw sensory information greater influence over conscious experience. This accounts for the dissolution of rigid cognitive patterns, ego loss, and the sense that perception is being encountered freshly.

Beyond acute effects, LSD promotes structural brain changes through two separable pathways. Moliner et al. demonstrated that LSD binds the TrkB receptor — a key mediator of BDNF signaling — with approximately 1,000-fold greater affinity than classical antidepressants.^[24] This plasticity mechanism operates independently of the psychedelic experience itself, raising the possibility that prodrug-delivered LSD may promote neural growth even at sub-perceptual doses.

Toxicity

By analogy with LSD, acute toxicity at typical doses is presumed very low. LSD has no confirmed human fatalities from overdose, and animal lethal doses are orders of magnitude above the active dose range.^[9]

Psychological risks

As an LSD prodrug, 1cP-LSD carries the full psychological risk profile of LSD.

Acute anxiety and panic increase substantially at higher doses, with ego dissolution and the dread of losing one's sense of self becoming prominent at 200 µg LSD-equivalent.^[5][25] Non-pharmacological factors — personality, psychological state, and environment — contribute substantially to whether an experience becomes distressing.^[6]

Psychosis precipitation is a well-established risk for individuals with personal or family history of psychotic disorders.^[9]

Hallucinogen Persisting Perception Disorder (HPPD) is a recognized risk with LSD-class compounds, ranging from brief, benign flashbacks (Type I) to chronic perceptual disturbances (Type II).^[26] Controlled research settings have found limited incidence, though long-term follow-up data remain inadequate.^[27] Pre-existing anxiety and visual symptoms may increase vulnerability.^[26] One published case documents HPPD in a 16-year-old, highlighting adolescent vulnerability to LSD-class compounds.^[28]

Tolerance and dependence

Tolerance develops rapidly after a single dose through 5-HT₂A downregulation in the frontal cortex.^[7] A single exposure to a serotonin receptor agonist produces measurable tolerance within 24 hours, with cross-tolerance to LSD.^[8] Full sensitivity resets in approximately 14 days.

Physical dependence does not develop with LSD or related lysergamides. No withdrawal has been documented.^[9]

Psychological dependence liability is considered low. LSD does not produce the reinforcement patterns associated with compulsive use, and rapid tolerance inherently limits dose escalation.^[9]

Drug interactions

SSRIs and SNRIs: Chronic SSRI use reduces LSD's psychedelic effects, likely through compensatory receptor changes.^[30]

MDMA: Co-administration with LSD significantly increases LSD blood levels and duration, and produces additive cardiovascular strain.^[31]

Contraindications

Contraindications are inferred from LSD class pharmacology. No 1cP-LSD-specific contraindication data have been published.

• Psychotic disorders and family history of psychosis: Absolute contraindication. LSD-class compounds can trigger acute psychotic episodes and may unmask latent psychotic illness.^[9]
• Bipolar disorder: Relative contraindication. Risk of manic episode. citation needed
• Lithium or other seizure-threshold-lowering medications: Absolute contraindication pending further evidence. safety citation needed
• Severe cardiovascular disease: Relative contraindication. LSD produces dose-dependent blood pressure and heart rate increases.^[5]
• Pregnancy: Absolute contraindication. No reproductive toxicity data exist. citation needed
• Adolescence: Relative contraindication. Developing brains may be more vulnerable to HPPD and other perceptual disturbances.^[28]

1cP-LSD occupies an ambiguous legal position in most jurisdictions. It is not explicitly scheduled in the majority of national drug control frameworks but may be captured by structural analog legislation, novel psychoactive substance blanket bans, or structural class provisions. Its confirmed status as a prodrug of the controlled substance LSD complicates classification. Legal status varies by jurisdiction and is subject to change; the information below reflects the best available data as of early 2026.

Analog and prodrug considerations

1cP-LSD's confirmed prodrug status creates a distinct legal vulnerability under analog legislation. In jurisdictions with functional analog provisions — notably the United States — the fact that 1cP-LSD converts to a Schedule I substance in the body strengthens the argument for "substantial similarity." Whether courts would apply the Federal Analogue Act to an N1-acylated LSD derivative has not been tested.

The German approach — banning structural classes under the NpSG — has proven more effective at capturing sequential lysergamide derivatives, though it has triggered the regulatory succession pattern described in the History section.^[4]